# Prevention of Unmitigated Chemotherapy-induced Emesis

> **NCT03996863** · NA · WITHDRAWN · sponsor: **Otolith Labs**

## Conditions studied

- Chemotherapy-induced Nausea and Vomiting
- Nausea Post Chemotherapy

## Interventions

- **DEVICE:** Otoband
- **DEVICE:** Placebo device

## Key facts

- **NCT ID:** NCT03996863
- **Lead sponsor:** Otolith Labs
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08-01
- **Primary completion:** 2019-08-01
- **Final completion:** 2019-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drexel Oncology was shut down a few days before first patient in.
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03996863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03996863, "Prevention of Unmitigated Chemotherapy-induced Emesis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03996863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*